Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Amgen's Asset Writedowns and Impairment history runs 4 years deep, the most recent figure standing at $400.0 million for Q3 2025.

• In Q3 2025, Asset Writedowns and Impairment rose 555.74% year-over-year to $400.0 million; the TTM figure through Mar 2026 stood at $400.0 million (down 55.11% YoY), while the FY2025 annual figure was $1.2 billion, up 654.72% from the prior year.
• Asset Writedowns and Impairment was $400.0 million for Q3 2025 at Amgen, down from $800.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $851.0 million in Q4 2023 to a low of $2.0 million in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $277.1 million across 4 years, with a median of $64.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Asset Writedowns and Impairment surged 42450.0% in 2023, then tumbled 96.47% in 2024.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $2.0 million in 2022, then soared by 42450.0% to $851.0 million in 2023, then sank by 96.47% to $30.0 million in 2024, then jumped by 1233.33% to $400.0 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $400.0 million (Q3 2025), $800.0 million (Q1 2025), and $30.0 million (Q4 2024), per Business Quant data.